Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/9/2025

Contrave Use in Thyroid Cancer Patients

Key Safety Considerations

  • The American Gastroenterological Association recommends verifying that uncontrolled hypertension is not present before prescribing Contrave, as it can elevate blood pressure and heart rate, making this an absolute contraindication 1, 2
  • The American Gastroenterological Association recommends verifying that seizure disorders or conditions predisposing to seizures are not present before prescribing Contrave, as the bupropion component lowers seizure threshold; maximum dose must not exceed 32 mg naltrexone/360 mg bupropion daily to maintain seizure risk at 0.1% 1, 2
  • The American Gastroenterological Association recommends verifying that current opioid use is not present before prescribing Contrave, as naltrexone is an opioid antagonist and will precipitate severe withdrawal 1, 2
  • The American Gastroenterological Association recommends verifying that eating disorders (bulimia or anorexia nervosa) are not present before prescribing Contrave, as it increases seizure risk 1, 2
  • The American Gastroenterological Association recommends verifying that pregnancy or inadequate contraception is not present before prescribing Contrave, as teratogenic effects cannot be ruled out 1
  • The American Gastroenterological Association recommends verifying that MAOI use within 14 days is not present before prescribing Contrave, as it risks hypertensive crisis 1
  • The American Gastroenterological Association recommends verifying that abrupt discontinuation of alcohol, benzodiazepines, or antiepileptic drugs is not present before prescribing Contrave, as it dramatically increases seizure risk 2

Relative Contraindications Requiring Dose Adjustment

  • The American Gastroenterological Association recommends a maximum dose of 150 mg daily (one tablet) for patients with moderate to severe hepatic impairment 1, 2
  • The American Gastroenterological Association recommends reducing the total daily dose by 50% for patients with moderate to severe renal impairment 1, 2

Dosing Protocol

  • The American Gastroenterological Association recommends a specific titration schedule to minimize adverse effects: Week 1: 8 mg naltrexone/90 mg bupropion once daily in the morning 1
  • The American Gastroenterological Association recommends a specific titration schedule to minimize adverse effects: Week 2: 8/90 mg twice daily 1
  • The American Gastroenterological Association recommends a specific titration schedule to minimize adverse effects: Week 3: 16 mg naltrexone/180 mg bupropion in the morning, 8/90 mg in the evening 1
  • The American Gastroenterological Association recommends a specific titration schedule to minimize adverse effects: Week 4 and beyond: 16/180 mg twice daily (maintenance dose) 1
  • The American Gastroenterological Association recommends taking the second dose before 3 PM to minimize insomnia risk 2

Monitoring Requirements

  • The American Gastroenterological Association recommends baseline assessment of blood pressure and heart rate measurement 1, 2
  • The American Gastroenterological Association recommends baseline assessment of mental status examination focusing on suicidal ideation, particularly in patients <24 years old 2
  • The American Gastroenterological Association recommends confirming that the patient is not taking opioid medications 2
  • The American Gastroenterological Association recommends blood pressure and heart rate monitoring, especially during the first 12 weeks, as Contrave can cause elevations 1, 2
  • The American Gastroenterological Association recommends monthly assessment for the first 3 months, then at least every 3 months 1
  • The American Gastroenterological Association recommends neuropsychiatric monitoring, watching for aggressiveness, depression, suicidal ideation, anxiety, sleep disorders, and psychotic symptoms 2
  • The American Gastroenterological Association recommends efficacy assessment at 12 weeks, and discontinuing if <5% weight loss 1

Critical Pitfalls to Avoid

  • The American Gastroenterological Association recommends not confusing Contrave with liraglutide, as only liraglutide has thyroid cancer contraindications 1
  • The American Gastroenterological Association recommends not exceeding the maximum dose, as seizure risk increases significantly above 32/360 mg daily 1, 2
  • The American Gastroenterological Association recommends not prescribing Contrave with concurrent opioid therapy, as it will precipitate withdrawal 1, 2
  • The American Gastroenterological Association recommends not ignoring blood pressure monitoring, as uncontrolled hypertension is an absolute contraindication and can worsen on therapy 1, 2
  • The American Gastroenterological Association recommends not continuing beyond 12 weeks without adequate response, and discontinuing if <5% weight loss 1

REFERENCES

2

Bupropion Dosing and Administration [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026